Endocrinology, Vol 122, 2667-2674, Copyright © 1988 by Endocrine Society

ARTICLES

Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and nonglycosylated forms

I Pellegrini, G Gunz, C Ronin, E Fenouillet, JP Peyrat, P Delori and P Jaquet
Laboratoire de Neuroendocrinologie Experimentale, Faculte de Medecine Nord, INSERM U 297, Marseille, France.

Multiple forms of PRL differing in their physicochemical and biological characteristics have been described. We have analyzed the molecular forms of human (h) PRL released in culture by pure hPRL-secreting tumors with a particular attention to glycosylated hPRL. The prolactinoma cells from six different tumors released, in serum-free conditions, 10-28 mg hPRL. The combination of polyacrylamide gel electrophoresis and immunoblotting techniques using a [125I]anti-hPRL monoclonal antibody allowed qualitative and quantitative analysis of the hPRL variants. The ratio of the glycosylated 25,000-mol wt form (G- hPRL) to the 23,000-mol wt nonglycosylated monomeric hPRL (NG-hPRL) varied from 0.13 to 0.25. Under the conditions of our studies, cleaved forms of the hormone (19,000 and 15,000 mol wt) accounted for less than 5% of the total immunoreactivity. G- and NG-hPRL were subsequently purified by gel filtration and lectin affinity chromatography. G-hPRL appeared fully sensitive to endoglycosidase F digestion, further supporting the presence of a freely accessible N-linked carbohydrate chain. When assayed for their ability to react with polyclonal antibodies directed against hPRL in a competitive RIA, G-hPRL was 3 times less immunoreactive than NG-hPRL. However, both types of hPRL exhibited superimposable displacement curves when tested in an immunoassay using an anti-hPRL monoclonal antibody. In binding studies using crude rabbit mammary gland membranes G-hPRL was half as potent as NG-hPRL. In stimulating the growth of the Nb2 lymphoma cell line, G- hPRL was 50% less active than NG-hPRL. Thus 1) under basal conditions, hPRL undergoes partial and variable glycosylation; 2) glycosylation of the hormone may modulate its immunoreactivity; 3) glycosylation of hPRL not only lowers its mammary gland receptor binding capacity but also its growth-promoting activity.

This article has been cited by other articles:

				D. Piwnica, P. Touraine, I. Struman, S. Tabruyn, G. Bolbach, C. Clapp, J. A. Martial, P. A. Kelly, and V. Goffin Cathepsin D Processes Human Prolactin into Multiple 16K-Like N-Terminal Fragments: Study of Their Antiangiogenic Properties and Physiological Relevance Mol. Endocrinol., October 1, 2004; 18(10): 2522 - 2542. [Abstract] [Full Text] [PDF]

				S. Vallette-Kasic, I. Morange-Ramos, A. Selim, G. Gunz, S. Morange, A. Enjalbert, P.-M. Martin, P. Jaquet, and T. Brue Macroprolactinemia Revisited: A Study on 106 Patients J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 581 - 588. [Abstract] [Full Text] [PDF]

				D W Montgomery Prolactin production by immune cells Lupus, October 1, 2001; 10(10): 665 - 675. [Abstract] [PDF]

				S. E. Hankinson, W. C. Willett, D. S. Michaud, J. E. Manson, G. A. Colditz, C. Longcope, B. Rosner, and F. E. Speizer Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, April 7, 1999; 91(7): 629 - 634. [Abstract] [Full Text] [PDF]